Aion Therapeutic Files Financials
Aion Therapeutic Files Financials
Toronto, Ontario--(Newsfile Corp. - November 7, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022, September 26, 2022, October 11, 2022 and October 31, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").
安大略省多倫多 —-(新聞檔公司-2022 年 11 月 7 日)- 永恆之塔治療公司（CSE：永恆之塔） (」永恆之塔療「或」公司「）宣布，在其 2022 年 9 月 13 日，2022 年 9 月 26 日，2022 年 10 月 11 日，2022 年 10 月 11 日和 2022 年 10 月 31 日發布的新聞稿中，它將根據國家政策 12-203 中規定的替代信息指南提供違約狀態報告 -連續披露違約的停止交易指令 (」NP「)。
On August 30, 2022, the Company announced (the "Default Announcement") that it had not filed its annual financial statements and management discussion and analysis for the year ended April 30, 2022, together with the related certification of filings under National Instrument 52-109 - Certification of Disclosure in Issuers' Annual and Interim Filings (collectively, the "Annual Disclosure Documents") by the prescribed deadline of August 29, 2022 and the subsequent delay in filing the Company's interim financial statement and management discussion and analysis for the three-month period ended July 31, 2022 (the "Interim Disclosure Documents") by the prescribed deadline of September 29, 2022.
本公司於 2022 年 8 月 30 日宣布（」預設公告「）沒有提交截至 2022 年 4 月 30 日止年度的年度財務報表和管理層討論和分析，以及根據國家儀表 52-109 申請的相關證明- 發行人年度及中期檔案披露的證明 (統稱為」年度披露文件「）在規定的截止日期為 2022 年 8 月 29 日，以及隨後提交公司截至 2022 年 7 月 31 日止三個月期間的中期財務報表和管理層討論和分析的隨後延遲（」中期披露文件「) 由規定的截止日期為 2022 年 9 月 29 日。
The Company is pleased to announce that it has filed its Annual Disclosure Documents and Interim Disclosure Documents and these documents can be accessed under the Company's profile at .
本公司欣然宣佈，已提交其年度披露文件及中期披露文件，有關文件可於本公司的個人資料下瀏覽。
About Aion Therapeutic Inc.
關於永恆之塔治療公司
Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.
Aion 治療公司通過其全資子公司 AI 製藥牙買加有限公司從事研究和開發，治療，數據挖掘和最先進的人工智能（機器學習）技術的業務，專注於使用來自大麻（大麻素），迷幻蘑菇（psilocybin），真菌（天然蘑菇）的化合物的組合藥物，營養品和化妝品的開發。）和其他藥用植物在法律環境中進行這種類型的發現。此外，永恆之塔治療正在創建與其發現相關的強大國際知識產權組合。
For further information, please contact:
欲了解更多信息，請聯繫：
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
永恆之塔治療公司
格雷厄姆·西蒙斯
執行副主席兼首席執行官
(416) 843-2881
DISCLAIMER & READER ADVISORY
免責聲明和讀者諮詢
Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.
本新聞稿中載列的若干資料可能包含前瞻性資訊，這些資料涉及重大的已知及未知風險及不明朗因素。這些前瞻性資訊會受到許多風險和不明朗因素的影響，其中某些風險和不明朗因素超出了公司的控制範圍，包括但不限於一般經濟狀況、行業狀況和依賴監管機構批准的影響。讀者請注意，擬備該等資料時所採用的假設，雖然在準備時被認為是合理的，但可能證明並不精確，因此，不應將不當的依賴置於前瞻性的資料上。除非適用證券法另有要求，否則雙方不承擔更新前瞻性信息的義務。
To view the source version of this press release, please visit
如欲查看此新聞稿的來源版本，請瀏覽
譯文內容由第三人軟體翻譯。